|
시장보고서
상품코드
1786982
세계의 시클로스포린 시장 규모, 점유율, 산업 분석 리포트 : 적응증별, 제형별, 투여 경로별, 유통 채널별, 지역별 - 시장 예측(2025-2034년)Cyclosporine Market Size, Share, & Industry Analysis Report By Indication (Transplant rejection prophylaxis, Rheumatoid arthritis), By Dosage Form, By Route of Administration, By Distribution Channel, and By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면 세계의 시클로스포린 시장 규모는 2034년까지 70억 6,000만 달러에 달할 전망입니다. 이 조사 리포트는 현재 시장 역학에 대한 상세 인사이트와 향후 시장 성장에 관한 분석을 제공하고 있습니다.
사이클로스포린은 장기이식 거부반응 예방 및 자가면역질환 관리에 널리 사용되는 면역억제제로, 정확한 면역조절이 치료의 성공에 필수적입니다. 엄격한 임상 프로토콜에 따라 개발되어 통제된 면역 반응과 일관된 치료 결과를 보장합니다. 의료 시스템이 전신 및 안과용 고급 면역 억제 요법에 대한 접근성을 확대함에 따라 시장은 계속 성장하고 있습니다.
시장 성장의 원동력은 정부의 의료비 지출 증가와 전 세계 장기 이식 건수 증가입니다. 약물 제제 및 전달 시스템의 발전으로 환자의 순응도 및 치료 효율이 향상되고 있습니다. 또한 자가면역질환과 만성 안구염증이 확대되면서 여러 진료과에서 시클로스포린의 임상 적용을 확대하는 원동력이 되고 있습니다.
사이클로스포린 시장 보고서의 하이라이트
적응증별로는 장기적인 면역억제요법이 필요한 신장, 간, 심장 이식 수술 건수가 증가함에 따라 이식 거부반응 예방이 2024년 시장을 주도했습니다.
제형별로는 안구건조증과 만성 안구표피염 진단 건수 증가로 인해 점안제 부문이 가장 빠르게 성장할 것으로 예측됩니다.
투여 경로별로는 경구용이 2024년 압도적인 시장 점유율을 차지할 것으로 예상되며, 이는 전신성 자가면역질환에 대한 사용과 병원 및 소매 채널에서 널리 이용 가능하기 때문으로 분석됩니다.
판매 채널별로는 병원내 약국이 2024년 압도적인 점유율을 차지했습니다. 이는 이식 후 투약 요법을 중앙에서 관리하고, 의사의 감독 하에 면역억제제를 조제하는 수요가 높기 때문입니다.
북미는 활발한 의료 지출과 제네릭 면역억제제 치료의 견고한 채택으로 인해 2024년 세계 사이클로스포린 시장에서 가장 큰 점유율을 차지할 것으로 예측됩니다.
아시아태평양은 장기 이식에 대한 접근성 증가와 자가면역질환 유병률 증가로 인해 예측 기간 중 가장 빠르게 성장할 것으로 예측됩니다.
세계의 주요 시장 기업에는 AbbVie Inc., AdvaCare Pharma, Apotex Inc., Cipla Ltd., Harrow, Inc., Lupin Pharmaceuticals, Inc., Novartis AG, Santen Pharmaceutical Co., Ltd., Strides Pharma Science Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries, Viatris Inc. 등이 있습니다.
목차
제1장 서론
제2장 개요
제3장 조사 방법
제4장 세계의 시클로스포린 시장 인사이트
- 시장 스냅숏
- 시클로스포린 시장 역학
- 촉진요인과 기회
- 정부 헬스케어비 지출의 확대
- 세계에서 장기 이식 수술의 증가
- 억제요인과 과제
- 대체 수단의 가용성
- 대체 레크리에이션 옵션과의 경쟁
- 촉진요인과 기회
- PESTEL 분석
- 시클로스포린 시장 동향
- 밸류체인 분석
제5장 세계의 시클로스포린 시장 : 적응증별
- 주요 조사 결과
- 서론
- 이식 거부반응 예방
- 류마티스 관절염
- 건선
- 자가면역성 중증근무력증
- 안구건조증
- 기타 적응증
제6장 세계의 시클로스포린 시장 : 제형별
- 주요 조사 결과
- 서론
- 캡슐
- 점안약
- 액체 용액
- 크림과 연고
제7장 세계의 시클로스포린 시장 : 투여 경로별
- 주요 조사 결과
- 서론
- 경구
- 정맥내
- 국소
제8장 세계의 시클로스포린 시장 : 유통 채널별
- 주요 조사 결과
- 서론
- 원내 약국
- 소매 약국
- 온라인 약국
제9장 세계의 시클로스포린 시장 : 지역별
- 주요 조사 결과
- 서론
- 시클로스포린 시장 분석 : 지역별, 2020-2034년
- 북미
- 북미 : 적응증별, 2020-2034년
- 북미 : 제형별, 2020-2034년
- 북미 : 투여 경로별, 2020-2034년
- 북미 : 유통 채널별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 적응증별, 2020-2034년
- 유럽 : 제형별, 2020-2034년
- 유럽 : 투여 경로별, 2020-2034년
- 유럽 : 유통 채널별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 적응증별, 2020-2034년
- 아시아태평양 : 제형별, 2020-2034년
- 아시아태평양 : 투여 경로별, 2020-2034년
- 아시아태평양 : 유통 채널별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 적응증별, 2020-2034년
- 중동 및 아프리카 : 제형별, 2020-2034년
- 중동 및 아프리카 : 투여 경로별, 2020-2034년
- 중동 및 아프리카 : 유통 채널별, 2020-2034년
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 적응증별, 2020-2034년
- 라틴아메리카 : 제형별, 2020-2034년
- 라틴아메리카 : 투여 경로별, 2020-2034년
- 라틴아메리카 : 유통 채널별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제10장 경쟁 구도
- 사업 확대·인수 분석
- 사업 확대
- 인수
- 제휴/협업/협정/공개
제11장 기업 개요
- AbbVie Inc.
- AdvaCare Pharma
- Apotex Inc.
- Cipla Ltd.
- Harrow, Inc.
- Lupin Pharmaceuticals, Inc.
- Novartis AG
- Santen Pharmaceutical Co., Ltd.
- Strides Pharma Science Ltd.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries
- Viatris Inc.
The cyclosporine market size is expected to reach USD 7.06 Billion by 2034, according to a new study by Polaris Market Research. The report "Cyclosporine Market Share, Size, Trends, Industry Analysis Report: By Indication (Transplant rejection prophylaxis, Rheumatoid arthritis, Psoriasis), By Dosage Form, By Route of Administration, By Distribution Channel, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Cyclosporine is an immunosuppressive agent widely used to prevent organ transplant rejection and manage autoimmune conditions, where precise immune modulation is crucial for treatment success. Developed under stringent clinical protocols, it ensures controlled immune response and consistent therapeutic outcomes. The market continues to grow as healthcare systems expand access to advanced immunosuppressive therapies for systemic and ophthalmic applications.
The market growth is fueled by rising government healthcare spending and the increasing number of organ transplantation procedures globally. The rising advancement in drug formulations and delivery systems are enhancing patient compliance and therapeutic efficiency. Additionally, the expanding prevalence of autoimmune disorders and chronic ocular inflammation is driving the broader clinical adoption of cyclosporine across multiple specialties.
Cyclosporine Market Report Highlights
Based on indication, the transplant rejection prophylaxis segment dominated the market in 2024, due to the rising number of kidney, liver, and heart transplant surgeries requiring long-term immunosuppressive therapy.
Based on dosage form, the eye drops segment is expected to witness the fastest growth, driven by increasing diagnoses of dry eye disease and chronic ocular surface inflammation.
Based on route of administration, the oral segment held the dominant market share in 2024, driven by its use in systemic autoimmune conditions and widespread availability across hospital and retail channels.
Based on distribution channel, the hospital pharmacies segment held the dominant share in 2024, due to the centralized management of post-transplant medication regimens and the high demand for physician-supervised dispensing of immunosuppressants.
North America accounted for largest share of the global cyclosporine market in 2024, fueled by strong healthcare spending and robust adoption of generic immunosuppressive therapies.
Asia Pacific is expected to grow fastest during the forecast period, due to increasing access to organ transplantation and growing prevalence of autoimmune diseases.
A few global key market players include AbbVie Inc., AdvaCare Pharma, Apotex Inc., Cipla Ltd., Harrow, Inc., Lupin Pharmaceuticals, Inc., Novartis AG, Santen Pharmaceutical Co., Ltd., Strides Pharma Science Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries, and Viatris Inc.
Polaris Market Research has segmented the market report on the basis of indication, dosage form, route of administration, distribution channel, and region:
By Indication Outlook (Revenue, USD Billion, 2020-2034)
Transplant rejection prophylaxis
Rheumatoid arthritis
Psoriasis
Autoimmune myasthenia gravis
Dry eye
Other indications
By Dosage Form Outlook (Revenue, USD Billion, 2020-2034)
Capsule
Eye drops
Liquid solutions
Creams and ointments
By Route of Administration (Revenue, USD Billion, 2020-2034)
Oral
Intravenous
Topical
By Distribution Channel (Revenue, USD Billion, 2020-2034)
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin Americ
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Cyclosporine Market Insights
- 4.1. Cyclosporine Market - Market Snapshot
- 4.2. Cyclosporine Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Government Healthcare Spending
- 4.2.1.2. Rising Cases of Organ Transplant Procedures Worldwide
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Availability of Alternatives
- 4.2.2.2. Competition from Alternative Recreational Options
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Cyclosporine Market Trends
- 4.6. Value Chain Analysis
5. Global Cyclosporine Market, by Indication Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 5.3. Transplant rejection prophylaxis
- 5.3.1. Global Cyclosporine Market, by Transplant rejection prophylaxis, by Region, 2020-2034 (USD Billion)
- 5.4. Rheumatoid arthritis
- 5.4.1. Global Cyclosporine Market, by Rheumatoid arthritis, by Region, 2020-2034 (USD Billion)
- 5.5. Psoriasis
- 5.5.1. Global Cyclosporine Market, by Psoriasis, by Region, 2020-2034 (USD Billion)
- 5.6. Autoimmune myasthenia gravis
- 5.6.1. Global Cyclosporine Market, by Autoimmune myasthenia gravis, by Region, 2020-2034 (USD Billion)
- 5.7. Dry eye
- 5.7.1. Global Cyclosporine Market, by Dry eye, by Region, 2020-2034 (USD Billion)
- 5.8. Other indications
- 5.8.1. Global Cyclosporine Market, by Other indications, by Region, 2020-2034 (USD Billion)
6. Global Cyclosporine Market, by Dosage Form
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 6.3. Capsule
- 6.3.1. Global Cyclosporine Market, by Capsule, by Region, 2020-2034 (USD Billion)
- 6.4. Eye drops
- 6.4.1. Global Cyclosporine Market, by Eye drops, by Region, 2020-2034 (USD Billion)
- 6.5. Liquid solutions
- 6.5.1. Global Cyclosporine Market, by Liquid solutions, by Region, 2020-2034 (USD Billion)
- 6.6. Creams and ointments
- 6.6.1. Global Cyclosporine Market, by Creams and ointments, by Region, 2020-2034 (USD Billion)
7. Global Cyclosporine Market, by Route of Administration
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 7.3. Oral
- 7.3.1. Global Cyclosporine Market, by Oral, by Region, 2020-2034 (USD Billion)
- 7.4. Intravenous
- 7.4.1. Global Cyclosporine Market, by Intravenous, by Region, 2020-2034 (USD Billion)
- 7.5. Topical
- 7.5.1. Global Cyclosporine Market, by Topical, by Region, 2020-2034 (USD Billion)
8. Global Cyclosporine Market, by Distribution Channel
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.3. Hospital pharmacies
- 8.3.1. Global Cyclosporine Market, by Hospital pharmacies, by Region, 2020-2034 (USD Billion)
- 8.4. Retail pharmacies
- 8.4.1. Global Cyclosporine Market, by Retail pharmacies, by Region, 2020-2034 (USD Billion)
- 8.5. Online pharmacies
- 8.5.1. Global Cyclosporine Market, by Online pharmacies, by Region, 2020-2034 (USD Billion)
9. Global Cyclosporine Market, by Geography
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Cyclosporine Market Assessment, By Geography, 2020-2034 (USD Billion)
- 9.3. Cyclosporine Market - North America
- 9.3.1. North America: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.3.2. North America: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.3.3. North America: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.3.4. North America: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.3.5. Cyclosporine Market - U.S.
- 9.3.5.1. U.S.: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.3.5.2. U.S.: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.3.5.3. U.S.: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.3.5.4. U.S.: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.3.6. Cyclosporine Market - Canada
- 9.3.6.1. Canada: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.3.6.2. Canada: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.3.6.3. Canada: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.3.6.4. Canada: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4. Cyclosporine Market - Europe
- 9.4.1. Europe: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.4.2. Europe: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.3. Europe: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.4. Europe: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.5. Cyclosporine Market - UK
- 9.4.5.1. UK: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.4.5.2. UK: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.5.3. UK: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.5.4. UK: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.6. Cyclosporine Market - France
- 9.4.6.1. France: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.4.6.2. France: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.6.3. France: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.6.4. France: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.7. Cyclosporine Market - Germany
- 9.4.7.1. Germany: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.4.7.2. Germany: Cyclosporine Market, by Dosage Form ,2020-2034 (USD Billion)
- 9.4.7.3. Germany: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.7.4. Germany: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.8. Cyclosporine Market - Italy
- 9.4.8.1. Italy: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.4.8.2. Italy: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.8.3. Italy: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.8.4. Italy: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.9. Cyclosporine Market - Spain
- 9.4.9.1. Spain: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.4.9.2. Spain: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.9.3. Spain: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.9.4. Spain: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.10. Cyclosporine Market - Netherlands
- 9.4.10.1. Netherlands: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.4.10.2. Netherlands: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.10.3. Netherlands: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.10.4. Netherlands: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.11. Cyclosporine Market - Russia
- 9.4.11.1. Russia: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.4.11.2. Russia: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.11.3. Russia: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.11.4. Russia: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.12. Cyclosporine Market - Rest of Europe
- 9.4.12.1. Rest of Europe: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.4.12.2. Rest of Europe: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.12.3. Rest of Europe: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.12.4. Rest of Europe: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5. Cyclosporine Market - Asia Pacific
- 9.5.1. Asia Pacific: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.5.2. Asia Pacific: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.3. Asia Pacific: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.4. Asia Pacific: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.5. Cyclosporine Market - China
- 9.5.5.1. China: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.5.5.2. China: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.5.3. China: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.5.4. China: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.6. Cyclosporine Market - India
- 9.5.6.1. India: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.5.6.2. India: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.6.3. India: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.6.4. India: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.7. Cyclosporine Market - Malaysia
- 9.5.7.1. Malaysia: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.5.7.2. Malaysia: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.7.3. Malaysia: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.7.4. Malaysia: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.8. Cyclosporine Market - Japan
- 9.5.8.1. Japan: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.5.8.2. Japan: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.8.3. Japan: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.8.4. Japan: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.9. Cyclosporine Market - Indonesia
- 9.5.9.1. Indonesia: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.5.9.2. Indonesia: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.9.3. Indonesia: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.9.4. Indonesia: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.10. Cyclosporine Market - South Korea
- 9.5.10.1. South Korea: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.5.10.2. South Korea: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.10.3. South Korea: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.10.4. South Korea: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.11. Cyclosporine Market - Australia
- 9.5.11.1. Australia: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.5.11.2. Australia: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.11.3. Australia: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.11.4. Australia: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.12. Cyclosporine Market - Rest of Asia Pacific
- 9.5.12.1. Rest of Asia Pacific: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.5.12.2. Rest of Asia Pacific: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.12.3. Rest of Asia Pacific: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.12.4. Rest of Asia Pacific: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6. Cyclosporine Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.6.2. Middle East & Africa: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.6.3. Middle East & Africa: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.4. Middle East & Africa: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6.5. Cyclosporine Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.6.5.2. Saudi Arabia: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.6.5.3. Saudi Arabia: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.5.4. Saudi Arabia: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6.6. Cyclosporine Market - UAE
- 9.6.6.1. UAE: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.6.6.2. UAE: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.6.6.3. UAE: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.6.4. UAE: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6.7. Cyclosporine Market - Israel
- 9.6.7.1. Israel: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.6.7.2. Israel: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.6.7.3. Israel: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.7.4. Israel: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6.8. Cyclosporine Market - South Africa
- 9.6.8.1. South Africa: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.6.8.2. South Africa: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.6.8.3. South Africa: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.8.4. South Africa: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6.9. Cyclosporine Market - Rest of Middle East & Africa
- 9.6.9.1. Rest of Middle East & Africa: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.6.9.2. Rest of Middle East & Africa: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.6.9.3. Rest of Middle East & Africa: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.9.4. Rest of Middle East & Africa: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.7. Cyclosporine Market - Latin America
- 9.7.1. Latin America: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.7.2. Latin America: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.7.3. Latin America: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.7.4. Latin America: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.7.5. Cyclosporine Market - Mexico
- 9.7.5.1. Mexico: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.7.5.2. Mexico: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.7.5.3. Mexico: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.7.5.4. Mexico: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.7.6. Cyclosporine Market - Brazil
- 9.7.6.1. Brazil: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.7.6.2. Brazil: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.7.6.3. Brazil: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.7.6.4. Brazil: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.7.7. Cyclosporine Market - Argentina
- 9.7.7.1. Argentina: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.7.7.2. Argentina: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.7.7.3. Argentina: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.7.7.4. Argentina: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.7.8. Cyclosporine Market - Rest of Latin America
- 9.7.8.1. Rest of Latin America: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.7.8.2. Rest of Latin America: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.7.8.3. Rest of Latin America: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.7.8.4. Rest of Latin America: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. AbbVie Inc.
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. AdvaCare Pharma
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. Apotex Inc.
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. Cipla Ltd.
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. Harrow, Inc.
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. Lupin Pharmaceuticals, Inc.
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. Novartis AG
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. Santen Pharmaceutical Co., Ltd.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. Strides Pharma Science Ltd.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. Sun Pharmaceutical Industries Ltd.
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
- 11.11. Teva Pharmaceutical Industries
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
- 11.12. Viatris Inc.
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development
